Karen M. Mann

3.7k total citations · 1 hit paper
16 papers, 1.1k citations indexed

About

Karen M. Mann is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Karen M. Mann has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Karen M. Mann's work include Cancer Genomics and Diagnostics (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and CRISPR and Genetic Engineering (3 papers). Karen M. Mann is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Pancreatic and Hepatic Oncology Research (4 papers) and CRISPR and Genetic Engineering (3 papers). Karen M. Mann collaborates with scholars based in United States, Singapore and New Zealand. Karen M. Mann's co-authors include Neal G. Copeland, Nancy A. Jenkins, Qingguang Jiang, Gary E. Landreth, Jill Richardson, Shweta Mandrekar, Jonathan D. Smith, Timothy M. Willson, Thomas A. Comery and Brandy Wilkinson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Communications.

In The Last Decade

Karen M. Mann

15 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ApoE Promotes the Proteolytic Degradation of Aβ

2008 716 citations Qingguang Jiang, Shweta Mandrekar et al. Neuron profile →

Peers

Countries citing papers authored by Karen M. Mann

Since Specialization

Citations

This map shows the geographic impact of Karen M. Mann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen M. Mann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen M. Mann more than expected).

Fields of papers citing papers by Karen M. Mann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen M. Mann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen M. Mann. The network helps show where Karen M. Mann may publish in the future.

Co-authorship network of co-authors of Karen M. Mann

This figure shows the co-authorship network connecting the top 25 collaborators of Karen M. Mann. A scholar is included among the top collaborators of Karen M. Mann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen M. Mann. Karen M. Mann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma 2025 ·Molecular Cancer ·(unknown), K. Humphrey, Eduardo Cortes Gomez, (unknown), Vishnu Kumarasamy, (unknown), Mark D. Long, Michael E. Feigin, Agnieszka K. Witkiewicz, Karen M. Mann, Erik S. Knudsen, Ethan V. Abel	0
2	POGK is a domesticated KRAB domain-containing transposable element with tumor suppressive functions in breast cancer 2024 ·Trends in Cell Biology ·Karen M. Mann	1
3	RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing 2023 ·Nature Communications ·Michelle Maurin, (unknown), (unknown), Justin Y. Newberg, Dongliang Du, (unknown), (unknown), (unknown), (unknown), Barbara A. Centeno, Shondra M. Pruett‐Miller, Paul A. Stewart, Jason B. Fleming, Xiaoqing Yu, Jose Javier Bravo‐Cordero, Ernesto Guccione, Michael A. Black, Karen M. Mann	21
4	Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation 2021 ·Cancers ·(unknown), (unknown), (unknown), Justin Y. Newberg, Jerrold M. Ward, Deborah A. Swing, Neal G. Copeland, Nancy A. Jenkins, Karen M. Mann, Michael B. Mann	1
5	Nanotrap-enabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection 2019 ·Nano Research ·Zaian Deng, Zhen Zhao, Bo Ning, (unknown), Karen M. Mann, Jie Fu, Yajun Gu, Yuanqing Ye, Xifeng Wu, Jia Fan, Paul J. Chiao, Ye Hu	5
6	SB Driver Analysis: a Sleeping Beauty cancer driver analysis framework for identifying and prioritizing experimentally actionable oncogenes and tumor suppressors 2018 ·Nucleic Acids Research ·Justin Y. Newberg, Michael A. Black, Nancy A. Jenkins, Neal G. Copeland, Karen M. Mann, Michael B. Mann	5
7	SBCDDB: Sleeping Beauty Cancer Driver Database for gene discovery in mouse models of human cancers 2017 ·Nucleic Acids Research ·Justin Y. Newberg, Karen M. Mann, Michael B. Mann, Nancy A. Jenkins, Neal G. Copeland	20
8	KRAS-related proteins in pancreatic cancer 2016 ·Pharmacology & Therapeutics ·Karen M. Mann, Haoqiang Ying, Joseph Juan, Nancy A. Jenkins, Neal G. Copeland	148
9	SBCapSeq Protocol: a method for selective cloning of Sleeping Beauty transposon insertions using liquid capture hybridization and Ion Torrent semiconductor sequencing 2016 ·Protocol Exchange ·Michael B. Mann, Karen M. Mann, Liliana Guzman‐Rojas, Felipe Amaya‐Manzanares, (unknown), Justin Y. Newberg, Nancy A. Jenkins, Neal G. Copeland	2
10	Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice 2015 ·Oncotarget ·Amanda M. Goh, Yuezhen Xue, Marc Leushacke, Ling Li, (unknown), (unknown), (unknown), Michael B. Mann, Karen M. Mann, Nick Barker, Guillermina Lozano, Tamara Terzian, David P. Lane	16
11	Transposon Insertional Mutagenesis Models of Cancer 2014 ·Cold Spring Harbor Protocols ·Karen M. Mann, Nancy A. Jenkins, Neal G. Copeland, Michael B. Mann	4
12	Sleeping Beauty mutagenesis: exploiting forward genetic screens for cancer gene discovery 2013 ·Current Opinion in Genetics & Development ·Michael B. Mann, Nancy A. Jenkins, Neal G. Copeland, Karen M. Mann	23
13	Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma 2012 ·Proceedings of the National Academy of Sciences ·Karen M. Mann, Jerrold M. Ward, (unknown), Anne Kovochich, David W. Dawson, Michael A. Black, Benjamin T. Brett, (unknown), Adam J. Dupuy, (unknown), David K. Chang, Andrew V. Biankin, Nicola Waddell, Karin S. Kassahn, Sean M. Grimmond, Alistair G. Rust, David J. Adams, Nancy A. Jenkins, Neal G. Copeland	165
14	Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity 2012 ·Proceedings of the National Academy of Sciences ·Amanda M. Goh, Chin Yan Lim, (unknown), Ling Li, Michael B. Mann, Karen M. Mann, Sergio Ménendez, David P. Lane	21
15	984 ELEVATED MARKERS OF APOPTOTIC CELL DEATH INDICATING NASH IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME 2009 ·Journal of Hepatology ·Sih Min Tan, Lars P. Bechmann, Sven Benson, (unknown), Harald Lahner, Tiina Dietz, Guido Gerken, Karen M. Mann, Ali Canbay	1
16	ApoE Promotes the Proteolytic Degradation of Aβ breakdown → 2008 ·Neuron ·Qingguang Jiang, (unknown), Shweta Mandrekar, Brandy Wilkinson, Paige E. Cramer, Noam Zelcer, Karen M. Mann, Bruce T. Lamb, Timothy M. Willson, Jon L. Collins, Jill Richardson, Jonathan D. Smith, Thomas A. Comery, David Riddell, David M. Holtzman, Peter Tontonoz, Gary E. Landreth	716

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact